Klas Wiman

About me
Publications
CV
Public outreach and news

About me

I am Professor of Molecular Cell and Tumor Biology at Karolinska Institutet since 1999. My main research interest is cancer and novel cancer therapy. For more than three decades, I have studied the tumor suppressor gene TP53. I was coordinator of an EU Integrated project (Mutp53) with 23 partners and a budget of 8 M Euros 2004-2009, and have co-edited two books on p53 (Springer 2005 and 2012). I have also co-founded the company Aprea Therapeutics with colleagues with the aim of developing novel p53-targeted anti-cancer drugs. More recently, my research has been supported by an ERC Advanced Grant.

Research

My laboratory performs research on p53 and the p53 tumor suppressor pathway, the p53 target gene Zmat3 (Wig-1), and therapeutic reactivation of mutant p53. We have identified the molecule APR-246 that can trigger apoptosis in TP53 mutant tumor cells and inhibit tumor growth in vivo in mice. It targets the cellular redox balance as well. APR-246 has been tested in several clinical trials in patients with MDS/AML. We are exploring the use of APR-246 for cancer prevention. We are also working on novel strategies for pharmacological induction of translational readthrough for reactivation of nonsense mutant TP53 in tumors.

Selected publications

Article: CELL DEATH & DISEASE. 2022;13(11):997
Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine
Palomar-Siles M; Heldin A; Zhang M; Strandgren C; Yurevych V; van Dinter JT; Engels SAG; Hofman DA; Ohlin S; Meineke B; Bykov VJN; van Heesch S; Wiman KG
Article: EMBO MOLECULAR MEDICINE. 2021;13(2):e10852
A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death
Ceder S; Eriksson SE; Cheteh EH; Dawar S; Corrales Benitez M; Bykov VJN; Fujihara KM; Grandin M; Li X; Ramm S; Behrenbruch C; Simpson KJ; Hollande F; Abrahmsen L; Clemons NJ; Wiman KG
Review: NATURE REVIEWS CANCER. 2018;18(2):89-102
Targeting mutant p53 for efficient cancer therapy
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(29):3633-3639
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Lehmann S; Bykov VJN; Ali D; Andren O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson P-O
Article: CANCER CELL. 2009;15(5):376-388
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Lambert JMR; Gorzov P; Veprintsev DB; Soderqvist M; Segerback D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJN
Review: CANCER CELL. 2007;12(4):303-312
Shaping genetic alterations in human cancer: The p53 mutation paradigm
Soussi T; Wiman KG

Articles

Journal article: AMERICAN SOCIETY OF CLINICAL ONCOLOGY EDUCATIONAL BOOK / ASCO. AMERICAN SOCIETY OF CLINICAL ONCOLOGY. MEETING. 2025;45(3):e473616
Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss-No Target Is Out of the Realm of Possibility.
Shah PA; Wiman KG; Cichowski K; Rodon Ahnert J
Article: CELL REPORTS. 2024;43(10):114784
Proteome-wide CETSA reveals diverse apoptosisinducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery
Ramos AD; Liang YY; Surova O; Bacanu S; Gerault M-A; Mandal T; Ceder S; Langeback A; Osterroos A; Ward GA; Bergh J; Wiman KG; Lehmann S; Prabhu N; Loof S; Nordlund P
Article: RNA BIOLOGY. 2023;20(1):368-383
Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN
Heldin A; Cancer M; Palomar-Siles M; Ohlin S; Zhang M; Sun-Zhang A; Mariani A; Liu J; Bykov VJN; Wiman KGG
Article: PLOS ONE. 2023;18(11):e0292468
Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene
Palomar-Siles M; Yurevych V; Bykov VJN; Wiman KG
Article: CELL DEATH & DISEASE. 2022;13(3):214
Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog
Zhang Q; Balourdas D-I; Baron B; Senitzki A; Haran TE; Wiman KG; Soussi T; Joerger AC
Article: CELL DEATH & DISEASE. 2021;12(7):709
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
Ceder S; Eriksson SE; Liang YY; Cheteh EH; Zhang SM; Fujihara KM; Bianchi J; Bykov VJN; Abrahmsen L; Clemons NJ; Nordlund P; Rudd SG; Wiman KG
Article: CELL DEATH AND DIFFERENTIATION. 2021;28(5):1477-1492
Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene
Doffe F; Carbonnier V; Tissier M; Leroy B; Martins I; Mattsson JSM; Micke P; Pavlova S; Pospisilova S; Smardova J; Joerger AC; Wiman KG; Kroemer G; Soussi T
Article: CELL DEATH DISCOVERY. 2020;6(1):42
Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells
Cheteh EH; Sarne V; Ceder S; Bianchi J; Augsten M; Rundqvist H; Egevad L; Ostman A; Wiman KG
Article: CLINICAL GENETICS. 2019;96(3):216-225
Functional characterization of novel germline TP53 variants in Swedish families
Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Bohm S; Lain S; Borg A; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
Article: TRANSLATIONAL ONCOLOGY. 2018;11(6):1343-1349
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
Synnott NC; Madden SF; Bykov VJN; Crown J; Wiman KG; Duffy MJ
Article: CELL CHEMICAL BIOLOGY. 2018;25(10):1219-1230.e3
Role of Thiol Reactivity for Targeting Mutant p53
Zhang Q; Bergman J; Wiman KG; Bykov VJN
Journal article: PLOS BIOLOGY. 2018;16(9):e3000030
Correction: WRAP53 Is Essential for Cajal Body Formation and for Targeting the Survival of Motor Neuron Complex to Cajal Bodies.
Mahmoudi S; Henriksson S; Weibrecht I; Smith S; Söderberg O; Strömblad S; Wiman KG; Farnebo M
Article: SCIENTIFIC REPORTS. 2018;8(1):12671
Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
Haffo L; Lu J; Bykov VJN; Martin SS; Ren X; Coppo L; Wiman KG; Holmgren A
Article: BLOOD. 2018;131(24):2670-2681
Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma
Ren W; Ye X; Su H; Li W; Liu D; Pirmoradian M; Wang X; Zhang B; Zhang Q; Chen L; Nie M; Liu Y; Meng B; Huang H; Jiang W; Zeng Y; Li W; Wu K; Hou Y; Wiman KG; Li Z; Zhang H; Peng R; Zhu S; Pan-Hammarstrom Q
Article: CELL DEATH & DISEASE. 2018;9(5):439
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang Q; Bykov VJN; Wiman KG; Zawacka-Pankau J
Journal article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2017;292(48):19607
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs (vol 280, pg 30384, 2005)
Bykov VJN; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
Article: CELL DEATH & DISEASE. 2017;8(6):e2848
Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death
Cheteh EH; Augsten M; Rundqvist H; Bianchi J; Sarne V; Egevad L; Bykov VJN; Ostman A; Wiman KG
Article: JOURNAL OF INTERNAL MEDICINE. 2017;281(5):483-495
Understanding cell cycle and cell death regulation provides novel weapons against human diseases
Wiman KG; Zhivotovsky B
Article: NATURE COMMUNICATIONS. 2017;8:14844
Inhibiting the system x_(C)over-bar/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu DS; Duong CP; Haupt S; Montgomery KG; House CM; Azar WJ; Pearson HB; Fisher OM; Read M; Guerra GR; Haupt Y; Cullinane C; Wiman KG; Abrahmsen L; Phillips WA; Clemons NJ
Article: FRONTIERS IN ONCOLOGY. 2017;7:323
Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
Zhang M; Heldin A; Palomar-Siles M; Ohlin S; Bykov VJN; Wiman KG
Journal article: MOLECULAR CELL. 2016;64(5):1009
Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage (vol 33, pg 462, 2009)
Mahmoudi S; Henriksson S; Corcoran M; Mendez-Vidal C; Wiman KG; Farnebo M
Article: JOURNAL OF OVARIAN RESEARCH. 2016;9(1):27
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
Fransson A; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
Article: CELL CYCLE. 2016;15(9):1267-1275
cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response
Madapura HS; Salamon D; Wiman KG; Lain S; Klein E; Nagy N
Article: ONCOTARGET. 2016;7(2):1895-1911
Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis
Bersani C; Huss M; Giacomello S; Xu L-D; Bianchi J; Eriksson S; Jerhammar F; Alexeyenko A; Vilborg A; Lundeberg J; Lui W-O; Wiman KG
Article: GUT. 2015;64(10):1506-1516
APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
Liu DSH; Read M; Cullinane C; Azar WJ; Fennell CM; Montgomery KG; Haupt S; Haupt Y; Wiman KG; Duong CP; Clemons NJ; Phillips WA
Article: CELL DEATH & DISEASE. 2015;6(6):e1794
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell N; Alfredsson J; Fransson A; Uustalu M; Bystrom S; Gullbo J; Hallberg A; Bykov VJN; Bjorklund U; Wiman KG
Article: ONCOGENE. 2014;33(35):4407-4417
Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3σ
Bersani C; Xu L-D; Vilborg A; Lui W-O; Wiman KG
Article: PLOS ONE. 2014;9(11):e111125
Expression of the p53 Target Wig-1 Is Associated with HPV Status and Patient Survival in Cervical Carcinoma
Xu L-D; Muller S; Thoppe SR; Hellborg F; Kanter L; Lerner M; Zheng B; Lagercrantz SB; Grander D; Wallin KL; Wiman KG; Larsson C; Andersson S
Article: GENES & DEVELOPMENT. 2014;28(1):58-70
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
Kelly GL; Grabow S; Glaser SP; Fitzsimmons L; Aubrey BJ; Okamoto T; Valente LJ; Robati M; Tai L; Fairlie WD; Lee EF; Lindstrom MS; Wiman KG; Huang DCS; Bouillet P; Rowe M; Rickinson AB; Herold MJ; Strasser A
Article: CELL DEATH & DISEASE. 2013;4(10):e881
APR-246/PRIMA-1^MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
Peng X; Zhang M-Q; Conserva F; Hosny G; Selivanova G; Bykov VJN; Arner ESJ; Wiman KG
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2013;110(6):2157-2162
APR-246/PRIMA-1^MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations
Shen J; van den Bogaard EH; Kouwenhoven EN; Bykov VJN; Rinne T; Zhang Q; Tjabringa GS; Gilissen C; van Heeringen SJ; Schalkwijk J; van Bokhoven H; Wiman KG; Zhou H
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2013;110(6):2152-2156
Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1^MET
Shalom-Feuerstein R; Serror L; Aberdam E; Mueller F-J; van Bokhoven H; Wiman KG; Zhou H; Aberdam D; Petit I
Article: CELL CYCLE. 2012;11(24):4563-4569
p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP
Madapura HS; Salamon D; Wiman KG; Lain S; Klein G; Klein E; Nagy N
Article: CELL DEATH & DISEASE. 2012;3(4):e298
Wig-1, a novel regulator of N-Myc mRNA and N-Myc-driven tumor growth
Vilborg A; Bersani C; Wickstrom M; Segerstrom L; Kogner P; Wiman KG
Article: ONCOGENE. 2010;29(49):6442-6451
PRIMA-1^MET/APR-246 targets mutant forms of p53 family members p63 and p73
Rokaeus N; Shen J; Eckhardt I; Bykov VJN; Wiman KG; Wilhelm MT
Article: PLOS BIOLOGY. 2010;8(11):e1000521
WRAP53 Is Essential for Cajal Body Formation and for Targeting the Survival of Motor Neuron Complex to Cajal Bodies
Mahmoudi S; Henriksson S; Weibrecht I; Smith S; Soderberg O; Stromblad S; Wiman KG; Farnebo M
Article: CARCINOGENESIS. 2010;31(8):1475-1482
Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein
Gouas DA; Shi H; Hautefeuille AH; Ortiz-Cuaran SL; Legros PC; Szymanska KJ; Galy O; Egevad LA; Abedi-Ardekani B; Wiman KG; Hantz O; de Fromentel CC; Chemin IA; Hainaut PL
Article: CARCINOGENESIS. 2010;31(6):1045-1053
Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells
Karimi M; Conserva F; Mahmoudi S; Bergman J; Wiman KG; Bykov VJN
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2010;396(1):85-89
The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer
Farnebo M; Bykov VJN; Wiman KG
Article: ONCOGENE. 2010;29(9):1329-1338
Mutant p53 reactivation by PRIMA-1^MET induces multiple signaling pathways converging on apoptosis
Lambert JMR; Moshfegh A; Hainaut P; Wiman KG; Bykov VJN
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2009;106(37):15756-15761
The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element
Vilborg A; Glahder JA; Wilhelm MT; Bersani C; Corcoran M; Mahmoudi S; Rosenstierne M; Grander D; Farnebo M; Norrild B; Wiman KG
Article: LEUKEMIA & LYMPHOMA. 2009;50(9):1512-1518
Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival
Paul E; Uggla B; Deneberg S; Bengtzen S; Hermansson M; Dahlman I; Rosenquist R; Wiman KG; Nahi H
Article: CELL CYCLE. 2009;8(16):2509-2517
Mutant p53 rescue and modulation of p53 redox state
Bykov VJN; Lambert JMR; Hainaut P; Wiman KG
Article: MOLECULAR CANCER. 2009;8:23
PRIMA-1^MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein
Stuber G; Flaberg E; Petranyi G; Otvos R; Rokaeus N; Kashuba E; Wiman KG; Klein G; Szekely L
Article: MOLECULAR CELL. 2009;33(4):462-471
Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage
Mahmoudi S; Henriksson S; Corcoran M; Mendez-Vidal C; Wiman KG; Farnebo M
Article: ONCOGENE. 2008;27(35):4854-4859
Proteomic identification of p53-dependent protein phosphorylation
Rahman-Roblick R; Hellman U; Becker S; Bader FG; Auer G; Wiman KG; Roblick UJ
Article: CARCINOGENESIS. 2008;29(7):1428-1434
In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249
Shi H; Lambert JMR; Hautefeuille A; Bykov VJN; Wiman KG; Hainaut P; de Fromentel CC
Article: FEBS LETTERS. 2008;582(15):2173-2177
The p53 target protein Wig-1 binds hnRNP A2/B1 and RNA Helicase A via RNA
Prahl M; Vilborg A; Palmberg C; Joernvall H; Asker C; Wiman KG
Article: MOLECULAR ONCOLOGY. 2008;2(1):70-80
Mutant p53 targeting by the low molecular weight compound STIMA-1
Zache N; Lambert JMR; Rokaeus N; Shen J; Hainaut P; Bergman J; Wiman KG; Bykou VN
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453
Mutated and non-mutated TP53 as targets in the treatment of leukaemia
Nahi H; Selivanova G; Lehmann S; Mollgard L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Article: RADIOTHERAPY AND ONCOLOGY. 2008;86(3):407-411
PRIMA-1^met radiosensitizes prostate cancer cells independent of their MTp53-status
Supiot S; Zhao H; Wiman K; Hill RP; Bristow RG
Article: CELLULAR ONCOLOGY. 2008;30(5):411-418
PRIMA-1^MET inhibits growth of mouse tumors carrying mutant p53
Zache N; Lambert JMR; Wiman KG; Bykov VJN
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2007;104(13):5401-5406
p53 targets identified by protein expression profiling
Rahman-Roblick R; Roblick UJ; Hellman U; Conrotto P; Liu T; Becker S; Hirschberg D; Jornvall H; Auer G; Wiman KG
Article: CELL DEATH AND DIFFERENTIATION. 2007;14(3):411-421
Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis
Liu T; Laurell C; Selivanova G; Lundeberg J; Nilsson P; Wiman KG
Article: ONCOGENE. 2007;26(7):982-992
PRIMA-1^MET induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins
Rokaeus N; Klein G; Wiman KG; Szekely L; Mattsson K
Article: FEBS LETTERS. 2006;580(18):4401-4408
The p53-induced Wig-1 protein binds double-stranded RNAs with structural characteristics of siRNAs and miRNAs
Vidal CM; Prahl M; Wiman KG
Article: CELL DEATH AND DIFFERENTIATION. 2006;13(6):921-926
Strategies for therapeutic targeting of the p53 pathway in cancer
Wiman KG
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236
PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(34):30384-30391
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
Bykov VJN; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
Article: ONCOGENE. 2005;24(21):3484-3491
PRIMA-1^MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov VJN; Zache N; Stridh H; Westman J; Bergman J; Selivanova G; Wiman KG
Article: ONCOGENE. 2005;24(8):1320-1327
hTERT antagonizes p53-induced apoptosis independently of telomerase activity
Rahman R; Latonen L; Wiman KG
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2004;24(6):1559-1564
The p53-induced Wig-1 zinc finger protein is highly conserved from fish to man
Hellborg F; Wiman KG
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2003;100(23):13303-13307
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
Issaeva N; Friedler A; Bozko P; Wiman KG; Fersht AR; Selivanova G
Article: EUROPEAN JOURNAL OF CANCER. 2003;39(13):1828-1834
Small molecules that reactivate mutant p53
Bykov VJN; Selivanova G; Wiman KG
Article: ONCOGENE. 2003;22(32):4993-5005
Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts
Lindström MS; Wiman KG
Article: ANNALS OF MEDICINE. 2003;35(7):458-465
Novel cancer therapy by reactivation of the p53 apoptosis pathway
Bykov VJN; Wiman KG
Article: CARCINOGENESIS. 2002;23(12):2011-2018
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
Bykov VJN; Issaeva N; Selivanova G; Wiman KG
Article: SEMINARS IN CANCER BIOLOGY. 2002;12(5):381-387
Role of genetic and epigenetic changes in Burkitt lymphoma
Lindström MS; Wiman KG
Article: INVESTIGATIONAL NEW DRUGS. 2002;20(3):253-259
A novel high-through-put assay for screening of pro-apoptotic drugs
Hägg M; Bivén K; Ueno T; Rydlander L; Björklund P; Wiman KG; Shoshan M; Linder S
Article: FEBS LETTERS. 2002;524(1-3):69-72
Identification of functional p53-binding motifs in the mouse wig-1 promoter
Wilhelm MT; Méndez-Vidal C; Wiman KG
Article: CANCER LETTERS. 2002;180(2):211-221
A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF
Hashemi J; Lindström MS; Asker C; Platz A; Hansson J; Wiman KG
Article: NUCLEIC ACIDS RESEARCH. 2002;30(9):1991-1996
The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity
Méndez-Vidal C; Wilhelm MT; Hellborg F; Qian W; Wiman KG
Article: ONCOGENE. 2002;21(14):2119-2129
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
Rippin TM; Bykov VJN; Freund SMV; Selivanova G; Wiman KG; Fersht AR
Article: NATURE MEDICINE. 2002;8(3):282-288
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov VJN; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
Article: ONCOGENE. 2001;20(39):5466-5474
Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein
Hellborg F; Qian W; Mendez-Vidal C; Asker C; Kost-Alimova M; Wilhelm M; Imreh S; Wiman KG
Article: ONCOGENE. 2001;20(17):2171-2177
p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53
Lindström MS; Klangby U; Wiman KG
Article: BRAIN PATHOLOGY. 2001;11(2):159-168
p14^ARF Deletion and methylation in genetic pathways to glioblastomas
Nakamura M; Watanabe T; Klangby U; Asker C; Wiman K; Yonekawa Y; Kleihues P; Ohgaki H
Article: APOPTOSIS. 2001;6(1-2):133-137
Inactivation of Myc-induced p53-dependent apoptosis in human tumors
Henriksson M; Selivanova G; Lindström M; Wiman KG
Article: ONCOGENE. 2000;19(45):5123-5133
Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells
Xu DW; Wang Q; Gruber A; Björkholm M; Chen ZG; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P
Article: CANCER RESEARCH. 2000;60(18):5278-5283
Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: Functional impact
Girnita L; Girnita A; Brodin B; Xie YT; Nilsson G; Dricu A; Lundeberg J; Wejde J; Bartolazzi A; Wiman KG; Larsson O
Article: EXPERIMENTAL CELL RESEARCH. 2000;256(2):400-410
Immunolocalization of human p14^ARF to the granular component of the interphase nucleolus
Lindström MS; Klangby U; Inoue R; Pisa P; Wiman KG; Asker CE
Article: GENE. 2000;246(1-2):247-254
p53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts
Magnusson KP; Sandström M; Ståhlberg M; Larsson M; Flygare J; Hellgren D; Wiman KG; Ljungquist S
Article: MOLECULAR CANCER RESEARCH. 2000;11(1):31-39
Polyoma virus middle T and small t antigens cooperate to antagonize p53-induced cell cycle arrest and apoptosis
Qian W; Wiman KG
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;265(1):1-6
p53-induced apoptosis as a safeguard against cancer
Asker C; Wiman KG; Selivanova G
Article: ANTICANCER RESEARCH. 1999;19(4B):2939-2943
Induction of the human ARF protein by serum starvation
Inoue R; Asker C; Klangby U; Pisa P; Wiman KG
Article: MOLECULAR AND CELLULAR BIOLOGY. 1999;19(5):3395-3402
Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain
Selivanova G; Ryabchenko L; Jansson E; Iotsova V; Wiman KG
Article: ONCOGENE. 1998;17(18):2333-2337
Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?
Magnusson KP; Satalino R; Qian W; Klein G; Wiman KG
Article: BLOOD. 1998;91(5):1680-1687
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma
Klangby U; Okan I; Magnusson KP; Wendland M; Lind P; Wiman KG
Article: SEMINARS IN CANCER BIOLOGY. 1998;8(5):369-378
Reactivation of mutant p53: a new strategy for cancer therapy
Selivanova G; Kawasaki T; Ryabchenko L; Wiman KG
Article: ONCOGENE. 1997;15(22):2699-2704
Wig-1, a new p53-induced gene encoding a zinc finger protein
VarmehZiaie S; Okan I; Wang YS; Magnusson KP; Warthoe P; Strauss M; Wiman KG
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1997;11(1):97-104
p53 overexpression in normal and dysplastic tissues adjacent to p53 negative squamous cell carcinomas of the head and neck
MunckWikland E; Blegen H; LewensohnFuchs I; Malec M; Auer G; Kuylenstierna R; Dalianis T; Wiman KG; Lindholm J
Article: NATURE MEDICINE. 1997;3(6):632-638
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
Selivanova G; Iotsova V; Okan I; Fritsche M; Strom M; Groner B; Grafstrom RC; Wiman KG
Article: JOURNAL OF GENERAL VIROLOGY. 1997;78:893-903
Role of p53 mutation in polyomavirus-induced tumorigenesis
Wang Q; Kashuba E; Magnusson KP; Pokrovskaja K; Okan I; Klein G; Wiman KG
Article: MOLECULAR CANCER RESEARCH. 1997;8(2):121-131
Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice
Shick L; Carman JH; Choi JK; Somasundaram K; Burrell M; Hill DE; Zeng YX; Wang YS; Wiman KG; Salhany K; Kadesch TR; Monroe JG; Donehower LA; ElDeiry WS
Article: MOLECULAR CANCER RESEARCH. 1996;7(12):1723-1732
Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines
Pokrovskaja K; EhlinHenriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Article: NUCLEIC ACIDS RESEARCH. 1996;24(18):3560-3567
The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region
Selivanova G; Iotsova V; Kiseleva E; Strom M; Bakalkin G; Grafstrom RC; Wiman KG
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;67(1):106-112
Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon gamma
Sangfelt O; Einhorn S; Bjorklund AC; Wiman KG; Okan I; Grander D
Article: ONCOGENE. 1996;12(12):2731-2735
Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis
Wang YS; Okan I; Pokrovskaja K; Wiman KG
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;66(3):322-325
Frequent expression of bcl-2 in renal-cell carcinomas carrying wild-type p53
Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
Article: BLOOD. 1996;87(8):3360-3367
Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage
Scuderi R; Palucka KA; Pokrovskaja K; Bjorkholm M; Wiman KG; Pisa P
Article: CURRENT OPINION IN CELL BIOLOGY. 1995;7(6):835-842
WHAT IS THE RESTRICTION POINT
ZETTERBERG A; LARSSON O; WIMAN KG
Article: ONCOGENE. 1995;11(10):1963-1969
MOUSE AND RAT B-MYC SHARE AMINO-ACID-SEQUENCE HOMOLOGY WITH THE C-MYC TRANSCRIPTIONAL ACTIVATOR DOMAIN AND CONTAIN A B-MYC SPECIFIC CARBOXY-TERMINAL REGION
ASKER CE; MAGNUSSON KP; PICCOLI SP; ANDERSSON K; KLEIN G; COLE MD; WIMAN KG
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1995;7(5):1123-1128
IDENTIFICATION OF GENES OVEREXPRESSED IN THE SQCC/Y1 HUMAN BUCCAL CARCINOMA CELL-LINE USING THE DIFFERENTIAL DISPLAY METHOD
SUNDQVIST K; IOTSOVA V; ZIAIE SV; WIMAN KG; HOOG C; GRAFSTROM RC
Article: JOURNAL OF GENERAL VIROLOGY. 1995;76:2423-2432
REVERSIBLE NUCLEOLAR TRANSLOCATION OF EPSTEIN-BARR VIRUS-ENCODED EBNA-5 AND HSP70 PROTEINS AFTER EXPOSURE TO HEAT-SHOCK OR CELL-DENSITY CONGESTION
SZEKELY L; JIANG WQ; POKROVSKAJA K; WIMAN KG; KLEIN G; RINGERTZ N
Article: CARCINOGENESIS. 1995;16(10):2515-2521
CHARACTERIZATION OF HUMAN BUCCAL EPITHELIAL-CELLS TRANSFECTED WITH THE SIMIAN-VIRUS-40 T-ANTIGEN GENE
KULKARNI PS; SUNDQVIST K; BETSHOLTZ C; HOGLUND P; WIMAN KG; ZHIVOTOVSKY B; BERTOLERO F; LIU Y; GRAFSTROM RC
Article: ONCOGENE. 1995;11(6):1027-1031
THE EBV-ENCODED LMP1 PROTEIN INHIBITS P53-TRIGGERED APOPTOSIS BUT NOT GROWTH ARREST
OKAN I; WANG YS; CHEN F; HU LF; IMREH S; KLEIN G; WIMAN KG
Article: MOLECULAR CANCER RESEARCH. 1995;6(9):1071-1075
BCL-2 INHIBITS WILD-TYPE P53-TRIGGERED APOPTOSIS BUT NOT G(1) CELL-CYCLE ARREST AND TRANSACTIVATION OF WAF1 AND BAX
WANG YS; OKAN I; SZEKELY L; KLEIN G; WIMAN KG
Article: EUROPEAN JOURNAL OF CANCER PART B: ORAL ONCOLOGY. 1995;31B(5):328-332
Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in nasopharyngeal carcinoma
Qian W; Hu LF; Chen F; Wang YS; Magnusson KP; Kashuba E; Klein G; Wiman KG
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;61(5):683-691
RB-RECONSTITUTED HUMAN RETINOBLASTOMA CELLS FORM RB-POSITIVE INTRAOCULAR AND INTRACEREBRAL BUT NOT SUBCUTANEOUS TUMORS IN SCID MICE
SZEKELY L; WANG YS; KLEIN G; WIMAN KG
Article: NUCLEIC ACIDS RESEARCH. 1995;23(3):362-369
P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH THE C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN
BAKALKIN G; SELIVANOVA G; YAKOVLEVA T; KISELEVA E; KASHUBA E; MAGNUSSON KP; SZEKELY L; KLEIN G; TERENIUS L; WIMAN KG
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1995;6(1):27-29
IN FRAME DELETION OF INTRON-7 IN THE P53 GENE IN A HUMAN TONSIL TUMOR
MAGNUSSON KP; BERKE Z; MUNCKWIKLAND E; LEWENSOHNFUCHS I; KLEIN G; DALLIANIS T; WIMAN KG
Show more

All other publications

Preprint: BIORXIV. 2025
Mice carrying nonsense mutant p53 develop spontaneous tumors with frequent metastases
Strandgren C; Rondahl V; Oppelt A-S; Öhlin S; Heldin A; Wiman KG
Review: NATURE REVIEWS CLINICAL ONCOLOGY. 2024;21(2):106-120
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval A; Strandgren C; Heldin A; Palomar-Siles M; Wiman KG
Review: UPSALA JOURNAL OF MEDICAL SCIENCES. 2024;129:e10719
Therapeutic targeting of TP53 nonsense mutations in cancer
Strandgren C; Wiman KG
Corrigendum: ONCOGENE. 2023;42(9):709
Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3s (vol 33, pg 4407, 2014)
Bersani C; Xu L-D; Vilborg A; Lui W-O; Wiman KG
Corrigendum: CELL DEATH & DISEASE. 2022;13(8):672
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells (vol 12, 709, 2021)
Ceder S; Eriksson SE; Liang YY; Cheteh EH; Zhang SM; Fujihara KM; Bianchi J; Bykov VJN; Abrahmsen L; Clemons NJ; Nordlund P; Rudd SG; Wiman KG
Corrigendum: CELL DEATH & DISEASE. 2019;10(10):769
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 (vol 9, 439, 2018)
Zhang Q; Bykov VJN; Wiman KG; Zawacka-Pankau J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):e14712
Impact of combined MRP1 inhibition and mutant p53 targeting compound APR-246
Ceder AS; Eriksson SE; Cheteh EH; Bykov VJN; Abrahmsen L; Wiman KG
Review: JOURNAL OF MOLECULAR CELL BIOLOGY. 2019;11(4):330-341
p53 as a hub in cellular redox regulation and therapeutic target in cancer
Eriksson SE; Ceder S; Bykov VJN; Wiman KG
Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2017;281(5):418-421
Introduction to Nobel Conference: 'The Cell Cycle and Cell Death in Disease'
Wiman KG; Zhivotovsky B
Corrigendum: CELL DEATH & DISEASE. 2017;8(4):e2751
APR-246/PRIMA-1^MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase (vol 4, e881, 2013)
Peng X; Zhang M-Q; Conserva F; Hosny G; Selivanova G; Bykov VJN; Arner ESJ; Wiman KG
Review: FRONTIERS IN ONCOLOGY. 2016;6:21
Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
Bykov VJN; Zhang Q; Zhang M; Ceder S; Abrahmsen L; Wiman KG
Review: CELL DEATH AND DIFFERENTIATION. 2015;22(8):1239-1249
TP53: an oncogene in disguise
Soussi T; Wiman KG
Review: FEBS LETTERS. 2014;588(16):2622-2627
Mutant p53 reactivation by small molecules makes its way to the clinic
Bykov VJN; Wiman KG
Editorial comment: CELL DEATH AND DIFFERENTIATION. 2013;20(11):1438-1439
p53 talks to PARP: the increasing complexity of p53-induced cell death
Wiman KG
Editorial comment: CELL DEATH AND DIFFERENTIATION. 2012;19(1):180-183
Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop
Blandino G; Deppert W; Hainaut P; Levine A; Lozano G; Olivier M; Rotter V; Wiman K; Oren M
Review: CELL DEATH AND DIFFERENTIATION. 2011;18(9):1434-1440
The p53 target Wig-1: a regulator of mRNA stability and stem cell fate?
Vilborg A; Bersani C; Wilhelm MT; Wiman KG
Review: ONCOGENE. 2010;29(30):4245-4252
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
Wiman KG
Review: JOURNAL OF MOLECULAR MEDICINE-JMM. 2010;88(7):645-652
Regulation of tumor suppressor p53 at the RNA level
Vilborg A; Wilhelm MT; Wiman KG
Editorial comment: LANCET ONCOLOGY. 2009;10(9):913-919
30 years and a long way into p53 research
Hainaut P; Wiman KG
Review: CANCER LETTERS. 2009;276(1):1-7
Regulation of p53R2 and its role as potential target for cancer therapy
Wang X; Zhenchuk A; Wiman KG; Albertioni F
Review: ONCOGENE. 2007;26(15):2243-2254
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova G; Wiman KG
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2007;97:321-338
Restoration of wild-type p53 function in human tumors: Strategies for efficient cancer therapy
Wiman KG
Review: MEDICAL ONCOLOGY. 1998;15(4):222-228
New p53-based anti-cancer therapeutic strategies
Wiman KG
Review: EXPERIMENTAL CELL RESEARCH. 1997;237(1):14-18
p53: Emergency brake and target for cancer therapy
Wiman KG
Review: LAKARTIDNINGEN. 1997;94(38):3268-3272
[New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
Wiman KG
Editorial comment: NATURE MEDICINE. 1997;3(8):839-840
An old acquaintance resurfaces in human mesothelioma
Wiman KG; Klein G
Other: GENE. 1995;162(2):231-234
A SPLICE DONOR SITE MUTATION RESULTS IN THE INSERTION OF 5 EXTRA AMINO-ACIDS INTO P53 FROM SEWA MOUSE SARCOMA-CELLS
MAGNUSSON KP; MINAROVITS J; KLEIN G; WIMAN KG
Other: ONCOGENE. 1995;10(9):1869-1874
RESTING B-CELLS, EBV-INFECTED B-BLASTS AND ESTABLISHED LYMPHOBLASTOID CELL-LINES DIFFER IN THEIR RB, P53 AND EBNA-5 EXPRESSION PATTERNS
SZEKELY L; POKROVSKAJA K; JIANG WQ; SELIVANOVA G; LOWBEER M; RINGERTZ N; WIMAN KG; KLEIN G
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 1995;66:143-180
P53 - A CELL-CYCLE REGULATOR ACTIVATED BY DNA-DAMAGE
SELIVANOVA G; WIMAN KG
Show more

Employments

Professor, Senior, Department of Oncology-Pathology, Karolinska Institutet, 2025-2025
Professor, Department of Oncology-Pathology, Karolinska Institutet, 1999-2025

Degrees and Education

Docent, Karolinska Institutet, 1987

About me

Research

Selected publications

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI